AtaiBeckley N.V. (NASDAQ:ATAI) has been named one of the 10 best stocks under $10 that could triple, according to a recent analysis. The clinical-stage biopharmaceutical company, focused on mental health therapies, recently secured inclusion in the Russell 2000 and Russell 3000 indices, effective June 29. This milestone is significant because over $12 trillion in assets are benchmarked to Russell indexes, potentially boosting demand for ATAI shares among index funds.
Russell Inclusion and Analyst Upgrade
The company announced on June 25 that it would join the small-cap Russell 2000 and the broader Russell 3000 after the annual reconstitution. The Russell 2000 tracks about 2,000 small-cap stocks, while the Russell 3000 covers roughly 3,000 stocks across market caps. This inclusion often leads to increased institutional buying as funds rebalance to match the indices.
On July 7, Canaccord Genuity raised its price target on ATAI from $15 to $17, implying an upside potential of over 227% from the stock's current price below $10. The firm maintained a Buy rating, citing progress in the company's clinical pipeline. The upgrade followed the completion of patient dosing in the Phase 2 Elumina trial of VLS-01 for treatment-resistant depression.
Pipeline Progress and Future Prospects
AtaiBeckley is developing several mental health treatments. Its lead candidate, BPL-003, is in Phase 2 trials for treatment-resistant depression and alcohol use disorder. Another asset, RL-007, targets cognitive impairment associated with schizophrenia. The company is also planning Phase 3 development for major depressive disorder and considering expansion into generalized anxiety disorder.
While ATAI presents a high-risk, high-reward opportunity, some analysts believe certain AI stocks may offer even greater returns in a shorter timeframe. However, for investors seeking exposure to the mental health biotech space, ATAI's recent index inclusion and analyst support highlight its potential for significant upside.